Glucagon-like peptide analogues for type 2 diabetes mellitus

Abstract

Publisher statement: This review is published as a Cochrane Review in the Cochrane Database of Systematic Reviews 2011, Issue 10. Cochrane Reviews are regularly updated as new evidence emerges and in response to comments and criticisms, and the Cochrane Database of Systematic Reviews should be consulted for the most recent version of the Review.' Shyangdan, D.S. et al. (2011). Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, Issue 10. Art. No.: CD006423.

A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets

“…GLP-1-like immunoreactivity was detected by a polyclonal and a monoclonal anti-GLP-1 antibody reacting, respectively, with the mid to C terminal region of GLP-1 [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19] and the amidated C-terminus of the peptide (see the Methods). These antibodies generated similar staining patterns with NCI-H716 cells and human islets (ESM Figs 2 and 3).…”

“…The corresponding spectra of the GLP-1(7-37) and GLP-1 (7-36) tryptic sequences were matched with the putative digested sequences of the peptides using the sequence editor implemented on BIOTOOLS. GLP-1(7-37) and GLP-1(7-36) peptides were identified by the species at m/z 1105 (aa [21][22][23][24][25][26][27][28] and at m/z 2098 (aa [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20].…”

“…Primary antibodies were: guinea pig polyclonal anti-swine insulin (A0564; DAKO, Carpinteria, CA, USA); mouse monoclonal anti-human/ mouse glucagon (MAB1249, clone 181402; R&D Systems, Abingdon, UK); rat monoclonal anti-somatostatin (ab30788; Abcam, Cambridge, UK); rabbit polyclonal anti-GLP-1 (ab22625; Abcam), which reacts with the mid to C terminal region of GLP-1 [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19], enabling immunoreactivity with N terminal truncated and C terminally extended forms of GLP-1; mouse monoclonal anti-GLP-1 (HYB 147-06; BioPorto Diagnostic, Gentofte, Denmark), which is specific for the amidated C-terminus of the peptide [20]; and rabbit polyclonal antibody to PC1/3 and PC2 (Chemicon, Rosemont, IL, USA). Secondary antibodies were: Alexa Fluor 488: goat anti-guinea pig IgG, goat anti-rabbit IgG, and goat anti-mouse IgG; and Alexa Fluor 594: goat anti-mouse IgG and goat antirabbit IgG (all from Invitrogen, Molecular Probes, Leiden, the Netherlands).…”

“…It also has or may have roles in the maintenance of beta cell mass, regulation of gastric motility, reduction of plasma glucagon, protection of endothelium, promotion of satiety and stimulation of glucose disposal [1-3, 5, 6]. The beneficial effects of GLP-1 and its mimetics on beta cells have made them potential therapeutic agents for type 2 diabetes [1][2][3][5][6][7]. However, the action of GLP-1 is limited in duration due to cleavage by dipeptidyl peptidase IV (DPP-4), resulting in a GLP-1 half-life of approximately 2 min [1-3, 5, 6].…”

GLP-1 receptor agonists or DPP-4 inhibitors: How to guide the clinician?

“…19 Il a été obtenu par la D'une façon générale, les agonistes des récepteurs au GLP-1 entraînent une réduction des taux d'hémoglobine glyquée (HbA1c) de l'ordre de 1 à 1,5 %, comparable à celle que l'on peut observer lors du passage à l'insuline chez des patients en échec du traitement oral. 15 Un avantage potentiel des agonistes des récepteurs au GLP-1 réside dans le fait que ces médicaments sont capables de provoquer un certain amaigrissement, par un effet anorexigène à la fois central et périphérique. 11 Cet amaigrissement est souvent le bien venu chez le patient DT2 et contraste avec la prise pondérale généralement observée avec l'insuline, les sulfamides ou les glitazones.…”